Personal information

Verified email addresses

Verified email domains

Virology, Vaccine Immunology, Pharmacology
Thailand

Activities

Employment (2)

Mahidol University: Bangkok, TH

2024-11 to present | Lecturer (Pharmacology)
Employment
Source: Self-asserted source
Suvichada Assawakosri

Bumrungrad International Hospital: Bangkok, TH

2018-06-01 to 2020-04-01 | IPD Pharmacist (IPD Pharmacy)
Employment
Source: Self-asserted source
Suvichada Assawakosri

Education and qualifications (2)

Chulalongkorn University Faculty of Medicine: Bangkok, TH

2020-01 to 2024-07 | Ph.D. (Pharmacology)
Education
Source: Self-asserted source
Suvichada Assawakosri

Mahidol University: Salaya, Nakhon Pathom, TH

2012-04 to 2018-04 | Pharm.D. (Pharmaceutical care)
Education
Source: Self-asserted source
Suvichada Assawakosri

Works (19)

Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination

Heliyon
2024-01 | Journal article
Contributors: Suvichada Assawakosri; Sitthichai Kanokudom; Nungruthai Suntronwong; Jira Chansaenroj; Chompoonut Auphimai; Pornjarim Nilyanimit; Preeyaporn Vichaiwattana; Thanunrat Thongmee; Thaneeya Duangchinda; Warangkana Chantima et al.
Source: check_circle
Crossref

SARS-CoV-2 reinfection with Omicron BA.2.75 subvariants in Thai Adults in Thailand

2023-11-27 | Preprint
Contributors: Suvichada Assawakosri; Natthinee Sudhinaraset; Jira Chansaenroj; Nungruthai Suntronwong; Sitthichai Kanokudom; Natach Nalinpakorn; Napat Tantipraphat; Amica Sethabutra; Sittisak Honsawek; Yong Poovorawan
Source: check_circle
Crossref

Neutralizing antibodies against Omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity

International Journal of Infectious Diseases
2023-09 | Journal article
Contributors: Nungruthai Suntronwong; Sitthichai Kanokudom; Suvichada Assawakosri; Preeyaporn Vichaiwattana; Sirapa Klinfueng; Harit Phowatthanasathian; Jira Chansaenroj; Donchida Srimuan; Thaksaporn Thatsanathorn; Thaneeya Duangchinda et al.
Source: check_circle
Crossref

Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023

Scientific Reports
2023-09-20 | Journal article
Part of ISSN: 2045-2322
Contributors: Jira Chansaenroj; Nungruthai Suntronwong; Sitthichai Kanokudom; Suvichada Assawakosri; Preeyaporn Vichaiwattana; Sirapa Klinfueng; Lakana Wongsrisang; Thanunrat Thongmee; Ratchadawan Aeemjinda; Nongkanok Khanarat et al.
Source: Self-asserted source
Suvichada Assawakosri

SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study

PLOS ONE
2023-04-27 | Journal article
Contributors: Nungruthai Suntronwong; Harapan Harapan; Preeyaporn Vichaiwattana; Sirapa Klinfueng; Jiratchaya Puenpa; Sitthichai Kanokudom; Suvichada Assawakosri; Jira Chansaenroj; Donchida Srimuan; Thaksaporn Thatsanatorn et al.
Source: check_circle
Crossref

Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens

International Journal of Infectious Diseases
2023-01 | Journal article
Contributors: Sitthichai Kanokudom; Jira Chansaenroj; Nungruthai Suntronwong; Suvichada Assawakosri; Ritthideach Yorsaeng; Pornjarim Nilyanimit; Ratchadawan Aeemjinda; Nongkanok Khanarat; Preeyaporn Vichaiwattana; Sirapa Klinfueng et al.
Source: check_circle
Crossref

The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: Safety and immunogenicity to Omicron BA.4/BA.5

2023-01-19 | Preprint
Contributors: Sitthichai Kanokudom; Jira Chansaenroj; Nungruthai Suntronwong; Suvichada Assawakosri; Ritthideach Yorsaeng; Pornjarim Nilyanimit; Ratchadawan Aeemjinda; Nongkanok Khanarat; Preeyaporn Vichaiwattana; Sirapa Klinfueng et al.
Source: check_circle
Crossref

SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during pre- and omicron-dominant wave, from January 2021 through November 2022, Thailand: Longitudinal study

2022-12-05 | Preprint
Contributors: Nungruthai Suntronwong; Preeyaporn Vichaiwattana; Sirapa Klinfueng; Jiratchaya Puenpa; Sitthichai Kanokudom; Suvichada Assawakosri; Jira Chansaenroj; Donchida Srimuan; Thaksaporn Thatsanatorn; Siriporn Songtaisarana et al.
Source: check_circle
Crossref

Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination

2022-11-27 | Preprint
Contributors: Suvichada Assawakosri; Sitthichai Kanokudom; Nungruthai Suntronwong; Jira Chansaenroj; Chompoonut Auphimai; Pornjarim Nilyanimit; Preeyaporn Vichaiwattana; Thanunrat Thongmee; Thaneeya Duangchinda; Warangkana Chantima et al.
Source: check_circle
Crossref

Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated followed by an mRNA vaccine in children aged 5 - 11 years

2022-11-10 | Preprint
Contributors: Nasamon Wanlapakorn; Sitthichai Kanokudom; Harit Phowatthanasathian; Jira Chansaenroj; Nungruthai Suntronwong; Suvichada Assawakosri; Ritthideach Yorsaeng; Pornjarim Nilyanimit; Preeyaporn Vichaiwattana; Sirapa Klinfueng et al.
Source: check_circle
Crossref

Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination

The Journal of Infectious Diseases
2022-10-17 | Journal article
Part of ISSN: 0022-1899
Part of ISSN: 1537-6613
Contributors: Suvichada Assawakosri; Sitthichai Kanokudom; Nungruthai Suntronwong; Chompoonut Auphimai; Pornjarim Nilyanimit; Preeyaporn Vichaiwattana; Thanunrat Thongmee; Thaneeya Duangchinda; Warangkana Chantima; Pattarakul Pakchotanon et al.
Source: Self-asserted source
Suvichada Assawakosri

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination

International Journal of Infectious Diseases
2022-09 | Journal article
Part of ISSN: 1201-9712
Contributors: Suvichada Assawakosri; Sitthichai Kanokudom; Jira Chansaenroj; Nungruthai Suntronwong; Chompoonut Auphimai; Pornjarim Nilyanimit; Preeyaporn Vichaiwattana; Thanunrat Thongmee; Thaneeya D; Warangkana Chantima et al.
Source: Self-asserted source
Suvichada Assawakosri

Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax™) after homologous and heterologous two-dose regimens

2022-09-09 | Preprint
Contributors: Sitthichai Kanokudom; Jira Chansaenroj; Nungruthai Suntronwong; Suvichada Assawakosri; Ritthideach Yorsaeng; Pornjarim Nilyanimit; Ratchadawan Aeemjinda; Nongkanok Khanarat; Preeyaporn Vichaiwattana; Sirapa Klinfueng et al.
Source: check_circle
Crossref

Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination

2022-06-27 | Preprint
Contributors: Nungruthai Suntronwong; Suvichada Assawakosri; Sitthichai Kanokudom; Ritthideach Yorsaeng; Chompoonut Auphimai; Thanunrat Thongmee; Preeyaporn Vichaiwattana; Thaneeya Duangchinda; Warangkana Chantima; Pattarakul Pakchotanon et al.
Source: check_circle
Crossref

Immunogenicity following two doses of BBIBP-CorV vaccine and a third booster dose with viral vector and Mrna COVID-19 vaccines against delta and omicron variants in prime immunized adults with two doses of BBIBP-CorV vaccine

2022-06-17 | Preprint
Contributors: Jira Chansaenroj; Nungruthai Suntronwong; Sitthichai Kanokudom; Suvichada Assawakosri; Ritthideach Yorsaeng; Preeyaporn Vichaiwattana; Sirapa Klinfueng; Lakana Wongsrisang; Donchida Srimuan; Thaksaporn Thatsanatorn et al.
Source: check_circle
Crossref

Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination

2022-04-28 | Preprint
Contributors: Nungruthai Suntronwong; Sitthichai Kanokudom; Chompoonut Auphimai; Suvichada Assawakosri; Thanunrat Thongmee; Preeyaporn Vichaiwattana; Thaneeya Duangchinda; Warangkana Chantima; Pattarakul Pakchotanon; Jira Chansaenroj et al.
Source: check_circle
Crossref

COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron

Vaccines
2022-03 | Journal article | Author
Contributors: Nungruthai Suntronwong; Ritthideach Yorsaeng; Jiratchaya Puenpa; Chompoonut Auphimai; Thanunrat Thongmee; Preeyaporn Vichaiwattana; Sitthichai Kanokudom; Thaneeya Duangchinda; Warangkana Chantima; Pattarakul Pakchotanon et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine

2022-03-02 | Preprint
Contributors: Sitthichai Kanokudom; Suvichada Assawakosri; Nungruthai Suntronwong; Jira Chansaenroj; Chompoonut Auphimai; Pornjarim Nilyanimit; Preeyaporn Vichaiwattana; Thanunrat Thongmee; Ritthideach Yorsaeng; Thaneeya Duangchinda et al.
Source: check_circle
Crossref

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine

Vaccines
2022-01 | Journal article | Author
Contributors: Sitthichai Kanokudom; Suvichada Assawakosri; Nungruthai Suntronwong; Chompoonut Auphimai; Pornjarim Nilyanimit; Preeyaporn Vichaiwattana; Thanunrat Thongmee; Ritthideach Yorsaeng; Donchida Srimuan; Thaksaporn Thatsanatorn et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎